The Florida Cancer Specialists & Research Institute, LLC 2022 Annual Report, produced by the FCS in-house Marketing team, has been recognized in the 4th Annual Healthcare Digital Marketing Awards, a prestigious national awards program that recognizes excellence in healthcare and medical marketing.
Fort Myers, Fla., December 20, 2023 – The Florida Cancer Specialists & Research Institute, LLC (FCS) 2022 Annual Report, produced by the FCS in-house Marketing team, has been recognized in the 4th Annual Healthcare Digital Marketing Awards, a prestigious national awards program that recognizes excellence in healthcare and medical marketing. FCS received a Gold Award for its Annual Recap to Stakeholders, entitled, Embracing Innovation and Collaboration to Advance and Transform Cancer Care.
“This recognition among the best in our industry is especially meaningful,” said Michelle Robey, FCS Vice President of Marketing. “Our 2022 Annual Recap is a comprehensive summary of the many noteworthy accomplishments across our practice that make an enormous impact on our patients, enabling them to enjoy all the special moments that matter most in their lives.”
FCS Chief Executive Officer Nathan H. Walcker said, “The talented professionals on our FCS Marketing team consistently demonstrate their remarkable creativity, dedication and effectiveness in creating and disseminating valuable and pertinent information to our many stakeholders.”
Entries were received from more than 1,000 healthcare and medical institutions from across the U.S. and judged by a panel of esteemed healthcare marketers, creative directors, and marketing professionals. Submissions encompassed digital healthcare marketing and advertising disseminated via websites, electronic communications, and mobile and social media. Gold awards were presented to 139 institutions.
The full list of the 2023 Healthcare Digital Marketing Awards winners can be found here: HDMA Awards 2023
You can revisit the FCS 2022 Annual Recap to Stakeholders here.
Petosemtamab and Pembrolizumab: A Promising Pair in HNSCC Treatment
July 2nd 2024In an interview, Cesar Augusto Perez, MD, delved into the findings from a phase 2 study evaluating petosemtamab plus pembrolizumab in patients with recurrent/metastatic head and neck squamous cell carcinoma.
Read More